MedTrace Logo

Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer

NCT01931046 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2020-09-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of AD5-SGE-REIC/Dkk-3 in patients with localized prostate cancer.

Conditions

Interventions

DRUG

Ad5-SGE-REIC/Dkk3

Ad5-SGE-REIC/Dkk-3, was designed to increase intracellular production REIC protein. The adenovirus vector is a transport mechanism to infuse the REIC protein into the cell providing a temporary transfusion of protein that induces apoptosis in target cancer cells, but does not appear to have a significant effect on normal tissues.

Sponsors & Collaborators

  • The Pacific Link Consulting Co

    collaborator OTHER

  • Momotaro-Gene Inc.

    lead INDUSTRY

Principal Investigators

  • Christopher J Kane, MD · University of California, San Diego

  • Brian J Miles, MD, FACS · Baylor College of Medicine and Methodist Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2018-07-06
Completion
2020-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01931046 on ClinicalTrials.gov